Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Mindpeak's HER2 low comes out on top in comparative study by Cypath

Mindpeak's HER2 low comes out on top in comparative study by Cypath

In a first of its kind comparative study, Mindpeak's CE-marked HER2 AI for breast cancer diagnosis was compared to three other commercial AIs (e.g. Visiopharm). Mindpeak's AI showed the highest accuracy of all AIs in terms of balanced clinical scores (88.1%) for HER2-low, higher than the score of the next best AI (67.3%) and higher than the concordance of pathologists with the reference score (85.5%). Furthermore, Mindpeak's AI received the highest scores in a usability evaluation of the AI softwares in all categories. This study was conducted by Cypath-RB together with Institut Gustave Roussy and was presented at the world's leading annual meeting for pathology, the USCAP 2023 (United States and Canadian Academy of Pathology), in New Orleans in mid-March.

Poster PDF

Find out more about our AI-based diagnostics

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mindpeak Breast IHC being displayed on a monitor